2 news items
Cassava Sciences Reports Clinical Updates On Phase 3 Trials Of Simufilam
SAVA
10 May 24
, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer's disease dementia. The goal is to evaluate overall
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
with mild-to-moderate Alzheimer's disease dementia. The goal is to evaluate overall risk/benefit for simufilam 100 mg twice-daily versus placebo
- Prev
- 1
- Next